Europe - EPA:ALNFL - FR0014003XT0 - Common Stock
The current stock price of ALNFL.PA is 1.07 EUR. In the past month the price decreased by -17.44%. In the past year, price decreased by -48.8%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 22.9 | 332.47B | ||
| AMG.DE | AMGEN INC | 13.64 | 139.38B | ||
| GIS.DE | GILEAD SCIENCES INC | 14.8 | 130.96B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 23.85 | 90.15B | ||
| ARGX.BR | ARGENX SE | 66.21 | 44.11B | ||
| 1AE.DE | ARGENX SE | 67.76 | 45.14B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.71B | ||
| 1BIIB.MI | BIOGEN INC | 9.49 | 19.37B | ||
| IDP.DE | BIOGEN INC | 9 | 19.22B | ||
| 1MDGL.MI | MADRIGAL PHARMACEUTICALS INC | N/A | 8.46B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.33B | ||
| 0QF.DE | MODERNA INC | N/A | 8.19B |
NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. The company is headquartered in Castelnau-Le-Lez, Occitanie and currently employs 4 full-time employees. The company went IPO on 2021-07-05. The firm's products help cure addictions through an approach based on botanical pharmaceutical agents. The company develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. The firm applies scientific approach to other drug candidate with an initial focus targeting the growing addiction to cannabis.
NFL BIOSCIENCES SA
199 rue Helene Boucher
Castelnau-le-Lez OCCITANIE FR
Employees: 4
Phone: 33411937667
NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. The company is headquartered in Castelnau-Le-Lez, Occitanie and currently employs 4 full-time employees. The company went IPO on 2021-07-05. The firm's products help cure addictions through an approach based on botanical pharmaceutical agents. The company develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. The firm applies scientific approach to other drug candidate with an initial focus targeting the growing addiction to cannabis.
The current stock price of ALNFL.PA is 1.07 EUR. The price decreased by -6.63% in the last trading session.
ALNFL.PA does not pay a dividend.
ALNFL.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALNFL.PA.
NFL BIOSCIENCES SA (ALNFL.PA) has a market capitalization of 13.56M EUR. This makes ALNFL.PA a Nano Cap stock.
You can find the ownership structure of NFL BIOSCIENCES SA (ALNFL.PA) on the Ownership tab.
ChartMill assigns a fundamental rating of 1 / 10 to ALNFL.PA. The financial health of ALNFL.PA is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ALNFL.PA reported a non-GAAP Earnings per Share(EPS) of -0.36. The EPS increased by 54.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.64% | ||
| ROE | -84.25% | ||
| Debt/Equity | 0.01 |
10 analysts have analysed ALNFL.PA and the average price target is 3.37 EUR. This implies a price increase of 214.58% is expected in the next year compared to the current price of 1.07.